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Figure 1 Schematic representation of the development in the treatment of advanced- stage HCC based on median overall survival (mOS) data 
from some recent trials. The arrows are proportional to the reported (grey) or hypothetical (blue) mOS indicated by the respective numbers. The 
green overlapping arrows represent respectively the real- world and the expected survival (ie, based on the selection of ‘ideal’ candidates for TACE) 
in BCLC- B patients. The list of trials is not exhaustive and, due to the heterogeneity of patients’ population, not suitable for direct cross- comparison 
between the trials. Atezo/Bev: combined atezolizumab and bevacizumab; pH, phase of clinical study; TACE, trans- arterial chemoembolisation.
Letters
Immune checkpoint inhibitors: 
use them early, combined and 
instead of TACE?
We read with interest the recent Gut 
roundtable paper by Gerbes et al. As high-
lighted by these authors, treatment of 
HCC has rapidly changed1: currently, four 
tyrosine kinase inhibitors, ramucirumab 
and two immune checkpoint inhibitors 
(ICP) are approved in different lines of 
treatment.2 3 Survival of patients with 
advanced disease have improved corre-
spondingly, and more progress is expected 
from the burgeoning of trials of ICP- based 
combination treatment schemas (figure 1).
Due to the increasing efficacy of phar-
macological treatment, many physicians 
are inclined to initiate systemic therapy, 
rather than trans- arterial chemoembo-
lisation (TACE), in patients with more 
advanced intermediate- stage HCC 
(patients with more numerous or large 
lesions) or to switch earlier from TACE 
to systemic treatment. This propensity is 
accentuated by studies increasingly high-
lighting some limitations of the current use 
of locoregional treatment: median overall 
survival (mOS) under TACE treatment, 
expected to amount to over 30 months 
in well- selected patients, doesn’t exceed 
20 months in population- based studies.4 
Moreover, repeated TACE are also known 
to cause some extent of unintended collat-
eral damage to non- tumour liver, since a 
deterioration of liver function has been 
observed in up to 30% of patients treated 
by TACE.5 Liver function being a major 
determinant of survival in HCC patients, 
this implies that TACE may not only be 
unnecessary, but even noxious in ‘non- 
responders’. With these facts in mind, 
and with mOS of Barcelona Clinic Liver 
Cancer (BCLC)- C patients approaching 2 
years,6–8 shouldn’t it be expected that this 
improving effectiveness of systemic treat-
ment would become even more evident in 
BCLC- B patients, and that systemic agents 
should be used instead of TACE in this 
tumour stage (figure 1)?
The likely answer is: no. For one, TACE 
may be effective in treating lesions not 
responsive to systemic treatment until 
‘unTACEable progression’ (a concept 
most recently applied by Masatoshi Kudo 
in the TACTICS trial); moreover, TACE 
might boost the response to immuno-
logical agents by causing tumour- specific 
antigen release. To this regard, with much 
emphasis put on the ‘abscopal’ effect, and 
with no exceptions known to us, current 
studies of combination treatment with 
TACE are designed to administer immu-
nological agents either during or after 
TACE.
We propose here a novel concept for 
treatment of intermediate- state HCC 
by which (1) ICP are initiated first, (2) 
TACE is performed only on detection of 
radiological progression, (3) is directed 
only towards single progressive lesions 
and (4) repeated until untreatable progres-
sion. This study design is implemented 
in the randomised study DEMAND 
(EUDRACT 2019-002430-36), where 
TACE candidates are randomised either to 
a TACE-‘on demand’ or to a synchronous- 
treatment arm with atezolizumab/bevaci-
zumab (figure 2).
This approach is based on the observation 
that objective response to ICP (expected in 
approximately one- third of all patients) 
translates into excellent survival9 and is 
evident early.10 Delaying the use of TACE to 
the time- point of progression (should this 
ever occur) and confining it to targeting of 
progressive lesions, will altogether reduce 
the number of patients and the propor-
tion of liver parenchyma exposed to the 
collateral damage potentially caused by 
TACE. Most likely, however, this will not 
lessen the beneficial immunogenic effect of 
locoregional treatment, which is thought 
to be independent of the targeted tumour 
volume (abscopal effect). Initiating ICP first 
will also leave tumour vessels open to drug 
delivery and to the access of circulating 
lymphocytes.
In summary, while systemic treatment 
alone might soon exceed the real- life bene-
fits of TACE, combination currently likely 
remains the best option. However, initiating 
ICP- based systemic treatment first would 
select treatment- resistant tumour lesions—
rather than individuals—as target of TACE. 
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Figure 2 Schematic representation of the DEMAND study, a randomised, two- arm non- comparative phase II study on the efficacy of atezolizumab 
and bevacizumab (Atezo/Bev) followed by on- demand selective TACE (sdTACE) on detection of disease progression (PD), or of initial synchronous 
treatment with TACE and Atezo/Bev on 24 months survival rate in the treatment of unresectable hepatocellular carcinoma patients. The use of local 
ablation is allowed for lesions which cannot be targeted sufficiently selectively by TACE. TACE, trans- arterial chemoembolisation.
This may not reduce the benefits of the 
combination but could save liver function, 
thus translating into a survival benefit and 
contributing to solve the yearlong dilemma 
of when to start and stop TACE.
Enrico N De Toni   
Correspondence to Prof enrico N De toni, 
Department of Medicine II, University Hospital, LMU 
Munich, Munich, Germany;  
 enrico. detoni@ med. uni- muenchen. de
Contributors eNDt has written this manuscript on 
behalf of the DeMAND study group.
Funding the author has not declared a specific grant 
for this research from any funding agency in the public, 
commercial or not- for- profit sectors.
Competing interests eNDt has served as a paid 
consultant for AstraZeneca, Bayer, BMs, eIsAI, eli 
Lilly & Co, Pfizer, IPseN, and roche. He has received 
reimbursement of meeting attendance fees and travel 
expenses from Arqule, BMs, Bayer, Celsion and roche 
and lecture honoraria from BMs and Falk. He has 
received third- party funding for scientific research from 
Arqule, AstraZeneca, BMs, Bayer, eli Lilly and roche.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; 
internally peer reviewed.
Open access this is an open access article distributed 
in accordance with the Creative Commons Attribution 
Non Commercial (CC BY- NC 4.0) license, which permits 
others to distribute, remix, adapt, build upon this work 
non- commercially, and license their derivative works on 
different terms, provided the original work is properly 
cited, appropriate credit is given, any changes made 
indicated, and the use is non- commercial. see: http:// 
creativecommons. org/ licenses/ by- nc/ 4. 0/.
© Author(s) (or their employer(s)) 2020. re- use 
permitted under CC BY- NC. No commercial re- use. see 
rights and permissions. Published by BMJ.
To cite De toni eN. Gut 2020;69:1887–1888.
Received 16 August 2019
revised 1 October 2019
Accepted 4 October 2019




enrico N De toni http:// orcid. org/ 0000- 0002- 8101- 
8207
RefeRences
 1 Gerbes A, Zoulim F, tilg H, et al. Gut roundtable 
meeting paper: selected recent advances in 
hepatocellular carcinoma. Gut 2018;67:380–8.
 2 Galle Pr, Forner A, Llovet JM, et al. eAsL clinical 
practice guidelines: management of hepatocellular 
carcinoma. J Hepatol 2018;69:182–236.
 3 De toni eN, schlesinger- raab A, Fuchs M, et al. 
Age independent survival benefit for patients with 
hepatocellular carcinoma (HCC) without metastases 
at diagnosis: a population- based study. Gut 
2020;69:168–76.
 4 Lencioni r, de Baere t, soulen MC, et al. Lipiodol 
transarterial chemoembolization for hepatocellular 
carcinoma: a systematic review of efficacy and safety 
data. Hepatology 2016;64:106–16.
 5 Peck- radosavljevic M, Kudo M, raoul J- L, et al. 
Outcomes of patients (Pts) with hepatocellular 
carcinoma (HCC) treated with transarterial 
chemoembolization (tACe): global OPtIMIs final 
analysis. J Clin Oncol 2018;36:4018.
 6 Lee Ms rB, Hsu CH, Numata K, et al. randomised 
efficacy and safety results for Atezolizumab (Atezo) + 
bevacizumab (Bev) in patients (Pts) with previously 
untreated, unresectable hepatocellular carcinoma 
(HCC). Annal Oncol 2019;30:LBA39.
 7 t PJ Y, Finn rs, Cheng AL, et al. CheckMate 459: a 
randomized, multi- center phase III study of nivolumab 
(NIVO) vs sorafenib (sOr) as first- line (1L) treatment in 
patients (Pts) with advanced hepatocellular carcinoma 
(aHCC). Annal Oncol 2019;30:LBA38.
 8 Finn rs, Merle P, Granito A, et al. Outcomes of 
sequential treatment with sorafenib followed by 
regorafenib for HCC: additional analyses from the 
phase III resOrCe trial. J Hepatol 2018;69:353–8.
 9 Yau t, Kang Y- K, Kim t- Y, et al. Nivolumab (NIVO) 
+ ipilimumab (IPI) combination therapy in patients 
(Pts) with advanced hepatocellular carcinoma 
(aHCC): results from CheckMate 040. J Clin Oncol 
2019;37:4012.
 10 Pishvaian MJ, Lee Ms, ryoo B- Y, et al. LBA26Updated 
safety and clinical activity results from a phase Ib study 
of atezolizumab + bevacizumab in hepatocellular 































ut: first published as 10.1136/gutjnl-2019-319658 on 14 O
ctober 2019. D
ow
nloaded from
 
